Impact of an innovative blood factor stewardship program on drug expense and patient care

American Journal of Health-System Pharmacy

Volumn 72, Issue 18, 2015, Pages 1579-1584

  Amerine, Lindsey B ^a   Chen, Sheh Li ^b   Daniels, Rowell ^a   Key, Nigel ^c   Eckel, Stephen F ^a   Savage, Scott W ^d  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b Hematology Oncology   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; CLINICAL PHARMACY; COMPUTERIZED PROVIDER ORDER ENTRY; CONTINUOUS INFUSION; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MONITORING; DRUG SAFETY; HEALTH PROGRAM; HEART SURGERY; HEMATOLOGIST; HEMOPHILIA A; HEMOPHILIA B; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; STAFF TRAINING; THORAX SURGERY; ECONOMICS; HEALTH SERVICES RESEARCH; HOSPITAL PHARMACY; NORTH CAROLINA; ORGANIZATION AND MANAGEMENT; PHARMACIST; PROFESSIONAL STANDARD; STANDARDS; TOTAL QUALITY MANAGEMENT; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; DRUG COSTS; FACTOR VIIA; HUMANS; NORTH CAROLINA; ORGANIZATIONAL CASE STUDIES; PATIENT CARE; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; QUALITY IMPROVEMENT; RECOMBINANT PROTEINS;

EID: 84973094142     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140722     Document Type: Article

References (17)

1. Owen PS, Golightly LK, MacLaren R et al. Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother. 2008; 42:771-6.
2. Arnold DM, Webert KE, Carruthers J et al. Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme. Haemophilia. 2007; 13:271-8.
3. Nowak MA, Nelson RE, Breidenback JL et al. Clinical and economic outcomes of a prospective antimicrobial stewardship program. Am J Health-Syst Pharm. 2012; 69:1500-8.
4. Palmer HR, Weston J, Gentry L et al. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health-Syst Pharm. 2011; 68:2170-4.
5. Lesprit P, Brun-Brisson C. Hospital antibiotic stewardship. Curr Opin Infect Dis. 2008; 21:344-9.
6. Martin C, Ofotokun I, Rapp R et al. Results of an antimicrobial control program at a university hospital. Am J Health-Syst Pharm. 2005; 62:732-8.
7. World Federation of Hemophilia. Guidelines for the management of hemophilia, 2nd edition (July 2012). www1.wfh.org/publication/files/pdf-1472.pdf (accessed 2015 Jul 20).
8. Bona RD, Weinstein RA, Weisman SJ et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol. 1989; 32:8-13.
9. Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother. 2002; 36:882-91.
10. Hurst D, Zabor S, Malianni D, Miller D. Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a minipump infusion device. Haemophilia. 1998; 4:785-9.
11. Didier ME, Fischer S, Maki DG. Reconstituted recombinant factor VIII can be safely infused continuously for at least three days: it is a poor microbial growth medium. Blood Coagul Fibrinolysis. 1998; 9:227-32.
12. Poppe LB, Eckel SF, Savage SW. A multidisciplinary approach to the assessment and implementation of continuous infusion factor products in hemophilia patients at an academic medical center. Am J Health-Syst Pharm. 2012; 69:522-6.
13. Masud F, Bostan F, Chi E et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth. 2009; 23:28-33.
14. Gandhi M, Pierce RA, Zhang L et al. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg. 2007; 2:32-40.
15. Mayer SA, Brun NC, Begtrup K et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008; 358:2127-37.
16. Fang M, Go A, Chang Y et al. 30 day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012; 43:1795-9.
17. Baker JR, Crudder SO, Riske B et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health. 2005; 95:1910-16.